{"id":"W4409822319","doi":"10.1158/1538-7445.am2025-ct075","title":"Abstract CT075: Phase 1a/1b dose-escalation study of efbalropendekin alfa (XmAb24306) as single-agent and with atezolizumab in solid tumors","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"Toxin Mechanisms and Immunotoxins","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Atezolizumab; Medicine; Solid tumor; Oncology; Internal medicine; Cancer; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00126755,0.001351747,0.001675871,0.0004640542,0.0004420935,0.001148163,0.0008896785,0.001133078,0.004574989],"category_scores_gemma":[0.0006901967,0.0005582399,0.001097871,0.0004663235,0.0008393636,0.000833168,0.0003409034,0.003587667,0.001315889],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001601821,"about_ca_system_score_gemma":0.002232723,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0015165,"about_ca_topic_score_gemma":0.003149242,"domain_scores_codex":[0.9996114,0.0001539403,0.00002350418,0.00007014007,0.00004605894,0.00009486223],"domain_scores_gemma":[0.999453,0.00005334473,0.00009628864,0.00004002055,0.00003717845,0.0003201368],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6237761,0.1195826,0.01298118,0.001017682,0.001093877,0.0005713005,0.0003780446,0.004417155,0.1217779,0.0004479928,0.00803452,0.1059217],"study_design_scores_gemma":[0.3308136,0.6363555,0.01830729,0.00004933673,0.000348496,0.0006479951,0.00005807397,0.001242192,0.008076417,0.0001543165,0.003912827,0.0000339518],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923429,0.001210964,0.0004102997,0.0003371705,0.00007196769,0.002142714,0.001833593,0.0001100854,0.001540377],"genre_scores_gemma":[0.9855362,0.0009787772,0.001531978,0.0007703481,0.0001002448,0.002503953,0.004561951,0.00002935656,0.003987154],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004574989,"threshold_uncertainty_score":0.01530486,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05615121560228441,"score_gpt":0.3970706711734598,"score_spread":0.3409194555711754,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}